The clinical reality of ADHD is that it manifests differently in every patient, often complicating the path to effective symptom control. While hyperactivity and inattention are widely recognized, symptoms in adult women frequently go unnoticed, leading to significant diagnostic delays. Vertical Pharmaceuticals argues that the key to bridging this gap lies in flexible, individualized treatment plans that allow healthcare providers to titrate medication dosages with greater accuracy.
In section Releases
Vertical Pharmaceuticals Highlights ADHD Treatment Precision
With ADHD Awareness Month underway, Vertical Pharmaceuticals is emphasizing the necessity of precise dose optimization for patients living with the disorder. As national diagnosis rates climb to approximately 11.7% among U.S. children and adolescents, the company aims to address gaps in symptom management through its extended-release methylphenidate product, RELEXXII.
Art Deas, CEO of Alora Pharmaceuticals, the parent company of Vertical, noted that providing providers with options for precision dosing is central to the firm's mission. By offering multiple tablet strengths, the company seeks to assist clinicians in navigating the complexities of long-term medication management. Patients and caregivers are encouraged to consult healthcare professionals to discuss symptoms and explore individualized care strategies, while the company maintains a list of advocacy organizations, including the National Institute of Mental Health and ADDitude Magazine, for ongoing educational support.
Comments (0)
No comments yet. Be the first!